Ocumension Therapeutics Stock Forecast

Stock Price Forecast

According to 2 analysts polled by S&P Global, Ocumension Therapeutics stock has a consensus rating of "Buy" and an average price target of $9.66. The average 1-year stock price forecast is 97.95% higher than the current stock price, while the lowest is $9.00 (+84.43%) and the highest is $10.32 (+111.48%).

Price Target: $9.66 (+97.95%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$9.00	$9.66	$9.66	$10.32
Change	+84.43%	+97.95%	+97.95%	+111.48%

* Price targets were last updated on Apr 3, 2026.

Analyst Ratings

The average analyst rating for Ocumension Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jul '25	Aug '25	Dec '25	Feb '26	Mar '26	Apr '26
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst CICC No rating	CICC	Buy Maintains $10.16	Buy	Maintains	$10.16	+108.20%	Apr 3, 2026

Financial Forecast

Revenue This Year

1.10B

from 804.35M

37.32%

from 804.35M

Revenue Next Year

1.42B

from 1.10B

28.97%

from 1.10B

EPS This Year

0.07

from -0.11

EPS Next Year

0.25

from 0.07

257.14%

from 0.07

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	56.15M	158.96M	246.37M	417.31M	804.35M	1.10B
Revenue Growth	328.73%	183.11%	54.99%	69.38%	92.75%	37.32%
Gross Profit	36.94M	102.92M	144.37M	225.07M	360.92M	582.08M
Gross Margin	65.78%	64.74%	58.60%	53.93%	44.87%	52.70%
Operating Income	-385.93M	-455.86M	-402.15M	-306.43M	-160.20M	36.79M
Net Income	-259.99M	-402.64M	-379.79M	-268.27M	-158.82M	31.83M
EPS	-	-	-	-	-0.11	0.07
Forward PE	-	-	-	-	265.99	60.12
Free Cash Flow	-580.44M	-404.46M	-480.30M	-344.38M	-433.07M	-144.00M
No. Analysts	-	-	-	-	-	2

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue	2026	2027	2028
High	1.1B
Avg	1.1B
Low	1.1B

Revenue Growth

Revenue Growth	2026	2027	2028
High	37.4%
Avg	37.3%
Low	37.3%

EPS Forecast

EPS	2026	2027	2028
High	0.07
Avg	0.07
Low	0.07

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-